secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001437749-26-008482
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene enters third-year NIH subaward with NYU for up to $8M for ALS expanded access program
--------------------------------------------------------------------------------

- Third-year subaward under $45.1M NIH grant; up to $8M for period 9/1/2025–8/31/2026.
- Funds support Expanded Access Program for CNM-Au8 treatment of amyotrophic lateral sclerosis (ALS).
- Subaward with New York University as prime awardee; replaces prior subaward with Columbia University for first two years.
- Either party may terminate with 30 days' notice; Company retains Background IP and no licenses granted to NYU or US Gov.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774926008482/0001437749-26-008482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774926008482/clnn20260316_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-008482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer